By Lina carolina 
Scientists and medics have developed an ultra-rapid method of genetically diagnosing brain tumours that will cut the time it takes to classify them from 6-8 weeks, to as little as two hours — which could improve care for thousands of patients each year in the UK. This groundbreaking development, detailed in a new study published in Neuro-Oncology, represents a paradigm shift in neuro-oncology, promising faster, more accurate diagnoses and potentially improved patient outcomes.
A New Era in Brain Tumour Diagnostics
The pioneering technique, spearheaded by researchers at the University of Nottingham in collaboration with clinicians at Nottingham University Hospitals NHS Trust (NUH), has already demonstrated remarkable efficacy during live surgical procedures. In a series of 50 brain tumour surgeries, the new approach was utilized to deliver rapid, intraoperative diagnoses. The results were nothing short of spectacular: a 100% success rate in providing diagnostic results in under two hours from surgery, with detailed tumour classifications achieved within minutes of genetic sequencing. Furthermore, the platform’s advanced sequencing capabilities enable a fully integrated diagnosis within 24 hours, a stark contrast to the protracted timelines of traditional methods.
The Urgent Need for Speed in Brain Tumour Diagnosis
The statistics surrounding brain tumours in the UK underscore the critical importance of this advancement. Every day, approximately 34 individuals receive a diagnosis of some form of brain tumour, translating to over 12,000 cases annually. For the most aggressive forms of brain cancer, the average survival rate can be less than a year. This grim reality highlights the immense pressure on the healthcare system and the desperate need for swift and effective interventions.
Traditionally, the diagnostic process for brain tumours has been a lengthy and arduous journey. Complex genetic tests are required to accurately classify these heterogeneous growths, and these tests have historically been sent to centralized analysis facilities for processing. The waiting period for full results, which inform patients about the specific type of tumour they have and their likely prognosis, can stretch to six to eight weeks or even longer. This prolonged uncertainty is not merely an inconvenience; it is a source of profound emotional distress for patients and their families, exacerbating anxiety during an already incredibly difficult time. Moreover, these delays can significantly postpone the commencement of vital treatments such as radiotherapy and chemotherapy, potentially diminishing their effectiveness and impacting survival chances.
The Nottingham Breakthrough: Precision and Speed Combined
The team of experts at the University of Nottingham has engineered an ultra-rapid method that effectively eliminates this debilitating delay. The speed of this new technology is so profound that it can yield diagnostic results within a mere couple of hours, with the potential to provide this critical information to surgeons during the operation. This intraoperative diagnostic capability could fundamentally alter surgical decision-making, allowing for more informed and potentially life-saving interventions.
Dr. Stuart Smith, a distinguished Neurosurgeon from the School of Medicine at the University and within NUH, emphasized the transformative nature of this development. "Traditionally, the process of diagnosing brain tumours has been slow and expensive," Dr. Smith stated. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision-making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time."
He further elaborated on the immediate surgical implications: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This ability to adapt surgical plans in real-time based on definitive genetic information represents a monumental leap forward in surgical precision and patient safety.
From Specimen to Diagnosis: A Streamlined Workflow
The current treatment pathway typically begins with an MRI scan to identify the presence of a tumour. Patients then consult with clinicians to discuss potential tumour types. For many, the next step involves surgery to obtain a tumour sample. This sample is then dispatched to centralized laboratories for intricate genetic testing to identify specific DNA abnormalities that define the tumour’s type. Historically, neuropathologists would examine tissue samples under a microscope to identify cell types. However, in recent years, the field has evolved, with tumour classification increasingly relying on the identification of DNA and genetic abnormalities. This shift, while scientifically advancing, has been hampered by technological limitations that historically rendered the process slow.
Professor Matt Loose, a biologist from the School of Life Sciences at the University of Nottingham, played a pivotal role in developing the core technology behind this breakthrough. He devised a method to sequence specific regions of human DNA with exceptional depth, utilizing portable sequencing devices from Oxford Nanopore Technologies. This innovative approach allows for the rapid examination of crucial parts of the human genome and enables the simultaneous sequencing of multiple DNA regions, thereby dramatically accelerating the entire diagnostic process.
The Technology Behind the Speed: Nanopore Sequencing and ROBIN
The team has successfully adapted Professor Loose’s method for the genetic testing of brain tumour samples. Central to this advancement is ROBIN, a sophisticated software tool that operates in conjunction with P2 PromethION nanopore sequencers. This technology functions by detecting minute changes in electrical current flow as individual DNA molecules pass through a nanopore – a minuscule hole – in a membrane.
Reflecting on the historical context, Professor Loose remarked, "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient." He continued, "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how it can be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
The key to rapid classification lies in focusing on specific genetic markers. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose explained. Methylation patterns are crucial epigenetic modifications that play a significant role in gene regulation and are increasingly recognized as powerful biomarkers for tumour classification and prognosis.
Once a tumour sample is surgically removed, it is transported to the pathology lab, where DNA is extracted before being sent to Professor Loose’s team for sequencing. This streamlined workflow minimizes pre-analytical delays.
A Game-Changer for Patients and Clinicians
Dr. Simon Paine, a Consultant Neuropathologist at NUH, hailed the new diagnostic method as "a game changer, it really is revolutionary." He underscored its dual benefits: "It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." This combination of speed and accuracy addresses two of the most significant challenges in current brain tumour management.
The ultimate goal is to make this advanced testing widely accessible. The Nottingham team is actively working towards rolling out this new testing protocol across NHS Trusts throughout the UK, aiming to democratize access to rapid and precise diagnoses.
Economic and Equity Implications
Beyond its clinical impact, the new method also presents significant economic advantages. "Not only is the test more accurate and quicker, but it is also cheaper than current methods," Professor Loose revealed. "Our calculations stand at around £450 per person, potentially less when scaled-up. There are a few reasons for this. Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them."
This cost-effectiveness is a critical factor in its potential for widespread adoption. By consolidating multiple tests into a single, rapid assay, the new method not only saves money but also reduces the logistical complexities associated with sending samples to various specialized laboratories.
The Brain Tumour Charity’s Perspective
The Brain Tumour Charity, a leading organization dedicated to improving the lives of those affected by brain tumours, has expressed strong support for this revolutionary technology. Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, stated, "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis."
Dr. Newman further emphasized the potential for this technology to address disparities in healthcare access. "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis. The BRAIN MATRIX Trial, funded by the Brain Tumour Charity, is now exploring how this technology can match patients to personalised clinical trials across the UK." This highlights the immediate next steps in integrating this innovation into broader research and clinical practice, with a focus on personalized treatment strategies and clinical trial recruitment.
A Glimpse into the Future of Neuro-Oncology
The development by the University of Nottingham and NUH represents a monumental stride in the fight against brain tumours. By compressing a diagnostic timeline that previously spanned weeks into mere hours, this ultra-rapid genetic sequencing method promises to alleviate patient suffering, enable more timely and effective treatment initiation, and ultimately, improve the prognosis for thousands of individuals annually. As the technology is poised for wider implementation across the NHS, it heralds a new era of precision medicine in neuro-oncology, where speed, accuracy, and patient well-being are paramount. The ongoing integration with initiatives like the BRAIN MATRIX Trial further underscores the commitment to leveraging this breakthrough for the development of personalized treatment plans and accelerated access to cutting-edge therapies.
